Hemochromatosis Differential Diagnoses

  • Author: Andrea Duchini, MD; Chief Editor: Julian Katz, MD   more...
 
Updated: Dec 1, 2011
 
 

Diagnostic Considerations

When evaluating a patient with suspected hemochromatosis, alcoholic liver disease, ineffective erythropoiesis with marrow hyperplasia, iron overload associated with chronic anemia, multiple transfusions, and porphyria cutanea tarda should also be considered. In addition, patients may have susceptibility to certain bacterial infections, such as Yersinia enterocolitica liver abscess, Y pseudotuberculosis sepsis, Vibrio vulnificus sepsis, and Listeria monocytogenes meningitis.[72] Also, take note of the increased risk of hepatoma in cirrhotic livers of patients with hemochromatosis.

Distinguishing hemochromatosis arthropathy from rheumatoid arthritis is important for several reasons. For example, patients with hereditary hemochromatosis do not require corticosteroid treatment. In addition, if a diagnosis of rheumatoid arthritis is made incorrectly, treatment with phlebotomy is not started early, and familial genetic counseling is not considered.[73]

Alcoholic liver disease

Patients with alcoholic disease include those who are heavy drinkers, perhaps of iron-containing fortified wines, who have cirrhosis. Liver biopsy in these patients may show a modest increase in iron; however, contrary to patients with hemochromatosis, the hepatic iron levels are relatively normal and iron stores are less than 4 g.

Ineffective erythropoiesis with marrow hyperplasia

Patients with hyperplastic erythroid marrow absorb an increased amount of iron to the point where they may have clinical iron overload. Examples include the hereditary sideroblastic anemias, severe alpha and beta thalassemia, and the myelodysplastic syndrome variants, such as refractory anemia with ringed sideroblasts (RARS).

Iron overload associated with chronic anemia

Patients who have iron overload due to chronic anemia have increased effective erythropoiesis and increased iron absorption. Examples include hereditary spherocytosis and acquired sideroblastic anemia.

Multiple transfusions

Hypertransfusion is performed in patients with beta thalassemia major, sickle cell anemia, refractory aplastic anemia, and myelodysplastic syndrome. Such patients may receive as many as 100 units of red blood cells, which contain as much as 20-25 g of iron, similar to or more than the amount retained in many symptomatic patients with hereditary hemochromatosis.

Porphyria cutanea tarda

Porphyria cutanea tarda is primarily a skin and liver disease that occurs in familial and sporadic forms. The cause of liver siderosis in sporadic porphyria cutanea tarda has not been established, but it may be related to a mutation in the HFE gene in most patients.

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Andrea Duchini, MD  Associate Professor of Medicine and Surgery, Director of Hepatology, University of Texas Medical Branch School of Medicine; Medical Director of Liver Transplantation, Department of Surgery, The Methodist Hospital

Andrea Duchini, MD is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and International Liver Transplantation Society

Disclosure: Nothing to disclose.

Coauthor(s)

Hady E Sfeir, MD  Clinical Assistant Professor of Medicine, Department of Internal Medicine, OSF St Francis Medical Center

Hady E Sfeir, MD is a member of the following medical societies: American Association of Clinical Endocrinologists and American Medical Association

Disclosure: Nothing to disclose.

David M Klachko, MD, MEd  Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Missouri-Columbia School of Medicine

David M Klachko, MD, MEd is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, Endocrine Society, Missouri State Medical Association, and Sigma Xi

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD  Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Vivek V Gumaste, MD Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center

Vivek V Gumaste, MD is a member of the following medical societies: American College of Gastroenterology and American Gastroenterological Association

Disclosure: Nothing to disclose.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int. Jul 2009;106(30):499-504, I. [Medline]. [Full Text].

  2. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol. 2002;64:663-80. [Medline].

  3. O'Reilly FM, Darby C, Fogarty J, Tormey W, Kay EW, Leader M, et al. Screening of patients with iron overload to identify hemochromatosis and porphyria cutanea tarda. Arch Dermatol. Sep 1997;133(9):1098-101. [Medline].

  4. Janssen MC, Swinkels DW. Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol. 2009;23(2):171-83. [Medline].

  5. Galbraith R. Heme oxygenase: who needs it?. Proc Soc Exp Biol Med. Dec 1999;222(3):299-305. [Medline].

  6. Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. Aug 15 2008;181(4):2723-31. [Medline]. [Full Text].

  7. Conrad ME, Umbreit JN, Moore EG. Iron absorption and transport. Am J Med Sci. Oct 1999;318(4):213-29. [Medline].

  8. Parkkila S, Niemelä O, Britton RS, Fleming RE, Waheed A, Bacon BR, et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology. Dec 2001;121(6):1489-96. [Medline].

  9. Rolfs A, Bonkovsky HL, Kohlroser JG, et al. Intestinal expression of genes involved in iron absorption in humans. Am J Physiol Gastrointest Liver Physiol. Apr 2002;282(4):G598-607. [Medline].

  10. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. Jan 2004;36(1):77-82. [Medline].

  11. Papanikolaou G, Politou M, Roetto A, Bosio S, Sakelaropoulos N, Camaschella C, et al. Linkage to chromosome 1q in Greek families with juvenile hemochromatosis. Blood Cells Mol Dis. Jul-Aug 2001;27(4):744-9. [Medline].

  12. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. May 2006;38(5):531-9. [Medline].

  13. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. Mar 16 2001;276(11):7806-10. [Medline].

  14. Fleming RE, Britton RS, Waheed A, et al. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis. Nov 2004;8(4):755-73, vii. [Medline].

  15. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. Aug 2001;108(4):619-23. [Medline]. [Full Text].

  16. Himmelmann A, Fehr J. Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. J Lab Clin Med. Mar 1999;133(3):229-36. [Medline].

  17. Bittencourt PL, Marin ML, Couto CA, et al. Analysis of HFE and non-HFE gene mutations in Brazilian patients with hemochromatosis. Clinics (Sao Paulo). 2009;64(9):837-41. [Medline].

  18. Ramrakhiani S, Bacon BR. Hemochromatosis: advances in molecular genetics and clinical diagnosis. J Clin Gastroenterol. Jul 1998;27(1):41-6. [Medline].

  19. Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. Mar 2002;122(3):646-51. [Medline].

  20. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. Jul 2009;50(1):94-101. [Medline].

  21. Wallace DF, Walker AP, Pietrangelo A, et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol. Apr 2002;36(4):474-9. [Medline].

  22. Solanas-Barca M, Mateo-Gallego R, Calmarza P, et al. Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia. J Clin Endocrinol Metab. Nov 2009;94(11):4391-7. [Medline].

  23. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. Feb 22 2003;361(9358):669-73. [Medline].

  24. Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet. May 2003;34(1):102-7. [Medline].

  25. Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood. Feb 15 2005;105(4):1803-6. [Medline].

  26. Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood. Jul 1 2003;102(1):371-6. [Medline].

  27. Hattori A, Wakusawa S, Hayashi H, et al. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res. Jun 2003;26(2):154-156. [Medline].

  28. Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. Jan 1 2005;105(1):376-81. [Medline].

  29. Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis. Apr 2002;13(2):80-8. [Medline].

  30. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA. May 2 2001;285(17):2216-22. [Medline].

  31. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. Apr 1997;34(4):275-8. [Medline]. [Full Text].

  32. Byrnes V, Ryan E, Barrett S, Kenny P, Mayne P, Crowe J. Genetic hemochromatosis, a Celtic disease: is it now time for population screening?. Genet Test. Summer 2001;5(2):127-30. [Medline].

  33. Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatol Int. Jul 29 2009;[Medline].

  34. Gochee PA, Powell LW. What's new in hemochromatosis. Curr Opin Hematol. Mar 2001;8(2):98-104. [Medline].

  35. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. Sep 2 1999;341(10):718-24. [Medline].

  36. Gehrke SG, Pietrangelo A, Kascák M, Braner A, Eisold M, Kulaksiz H, et al. HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet. May 2005;67(5):425-8. [Medline].

  37. Adams PC, Barton JC. Haemochromatosis. Lancet. Dec 1 2007;370(9602):1855-60. [Medline].

  38. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. Apr 28 2005;352(17):1769-78. [Medline].

  39. Gleeson F, Ryan E, Barrett S, et al. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol. Sep 2004;16(9):859-63. [Medline].

  40. Acton RT, Barton JC, Bell DS, Go RC, Roseman JM. HFE mutations in African-American women with non-insulin-dependent diabetes mellitus. Ethn Dis. Fall 2001;11(4):578-84. [Medline].

  41. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. Jan 17 2008;358(3):221-30. [Medline].

  42. Barton JC, Wiener HW, Acton RT, et al. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis. Jan-Feb 2005;34(1):38-47. [Medline].

  43. Rivers CA, Barton JC, Gordeuk VR, et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. May-Jun 2007;38(3):247-52. [Medline].

  44. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. Nov 23 2000;343(21):1529-35. [Medline].

  45. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med. Jul 15 1997;127(2):105-10. [Medline].

  46. Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol. 1994;356:293-302. [Medline].

  47. Milman N, Pedersen P, á Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol. Dec 2001;80(12):737-44. [Medline].

  48. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med. Dec 1 1998;129(11):946-53. [Medline].

  49. Bathum L, Christiansen L, Nybo H, Ranberg KA, Gaist D, Jeune B, et al. Association of mutations in the hemochromatosis gene with shorter life expectancy. Arch Intern Med. Nov 12 2001;161(20):2441-4. [Medline].

  50. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol. Jan 1998;35(1):55-71. [Medline].

  51. Centers for Disease Control and Prevention (CDC). Iron overload and hemochromatosis. May 2006;[Full Text].

  52. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology. Jun 1998;27(6):1695-9. [Medline].

  53. Martinelli AL, Franco RF, Villanova MG, Figueiredo JF, Secaf M, Tavella MH, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?. Acta Haematol. 2000;102(3):152-6. [Medline].

  54. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. Feb 1998;114(2):311-8. [Medline].

  55. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. Sep 1999;31(3):421-9. [Medline].

  56. O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH. Declining prevalence of diabetes mellitus in hereditary haemochromatosis--the result of earlier diagnosis. Diabetes Res Clin Pract. Sep 2008;81(3):316-20. [Medline].

  57. Bailey EJ, Gardner AB. Hemochromatosis of the foot and ankle. Report of three cases and review of the literature. Clin Orthop Relat Res. Apr 1998;108-15. [Medline].

  58. Ellervik C, Tybjaerg-Hansen A, Grande P, Appleyard M, Nordestgaard BG. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation. Jul 12 2005;112(2):185-93. [Medline].

  59. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. Apr 2009;20(4):549-55. [Medline].

  60. McCullen MA, Crawford DH, Hickman PE. Screening for hemochromatosis. Clin Chim Acta. Jan 2002;315(1-2):169-86. [Medline].

  61. [Guideline] Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. Jul 2011;54(1):328-43. [Medline]. [Full Text].

  62. Wetterhall SF, Cogswell ME, Kowdley KV. Public health surveillance for hereditary hemochromatosis. Ann Intern Med. Dec 1 1998;129(11):980-6. [Medline].

  63. Cogswell ME, McDonnell SM, Khoury MJ, et al. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med. Dec 1 1998;129(11):971-9. [Medline].

  64. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. Jan 19 2002;359(9302):211-8. [Medline].

  65. Wojcik JP, Speechley MR, Kertesz AE, et al. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol. May 2002;16(5):297-302. [Medline].

  66. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. Feb 13 2006;166(3):294-301. [Medline].

  67. McDonnell SM, Phatak PD, Felitti V, et al. Screening for hemochromatosis in primary care settings. Ann Intern Med. Dec 1 1998;129(11):962-70. [Medline].

  68. Edwards CQ, Griffen LM, Ajioka RS, et al. Screening for hemochromatosis: phenotype versus genotype. Semin Hematol. Jan 1998;35(1):72-6. [Medline].

  69. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. May 2000;31(5):1160-4. [Medline].

  70. Lyon E, Frank EL. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem. 2001;47(7):1147-56. [Medline].

  71. Adams PC. Role of genetic testing and liver biopsy in the diagnosis of hemochromatosis. Curr Gastroenterol Rep. Feb-Mar 1999;1(1):27-9. [Medline].

  72. Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol. Apr 3 2009;[Medline].

  73. Brittenham GM, Weiss G, Brissot P, Lainé F, Guillygomarc'h A, Guyader D, et al. Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. Hematology Am Soc Hematol Educ Program. 2000;39-50. [Medline].

  74. Qaseem A, Aronson M, Fitterman N, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Oct 4 2005;143(7):517-21. [Medline].

  75. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology. Feb 2001;120(3):718-25. [Medline].

  76. Brandhagen DJ, Fairbanks VF, Baldus W. Recognition and management of hereditary hemochromatosis. Am Fam Physician. Mar 1 2002;65(5):853-60. [Medline].

  77. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. Apr 15 2003;138(8):627-33. [Medline].

  78. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol. 2000;32(1 Suppl):48-62. [Medline].

  79. McDonnell SM, Witte DL, Cogswell ME, et al. Strategies to increase detection of hemochromatosis. Ann Intern Med. Dec 1 1998;129(11):987-92. [Medline].

  80. Powell LW, George DK, McDonnell SM, et al. Diagnosis of hemochromatosis. Ann Intern Med. Dec 1 1998;129(11):925-31. [Medline].

  81. Swinkels DW, Jorna AT, Raymakers RA. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med. Dec 2007;65(11):452-5. [Medline].

  82. Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver. Semin Diagn Pathol. Nov 1998;15(4):237-45. [Medline].

  83. Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol. Nov 2001;116(5):738-43. [Medline].

  84. Worwood M. Pathogenesis and management of haemochromatosis. Br J Haematol. Apr 1999;105 Suppl 1:16-8. [Medline].

  85. Durupt S, Durieu I, Nové-Josserand R, Bencharif L, Rousset H, Vital Durand D. [Hereditary hemochromatosis]. Rev Med Interne. Nov 2000;21(11):961-71. [Medline].

  86. Bismuth M, Peynaud-Debayle E, for the Haute Autorite de Sante (HAS) guidelines department. Management of patients with HFE-related haemochromatosis (type 1 haemochromatosis) (July 2005). Available at http://www.has-sante.fr/portail/upload/docs/application/pdf/hemochromatosis_guidelines_2006_09_12__9_10_9_659.pdf. Accessed June 10, 2011.

  87. Brissot P, Troadec MB, Bardou-Jacquet E, Le Lan C, Jouanolle AM, Deugnier Y, et al. Current approach to hemochromatosis. Blood Rev. Jul 2008;22(4):195-210. [Medline].

  88. Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. Aug 2006;44(2):472-7. [Medline].

  89. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med. Dec 1 1998;129(11):932-9. [Medline].

  90. Nick H. Iron chelation, quo vadis?. Curr Opin Chem Biol. Aug 2007;11(4):419-23. [Medline].

  91. Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, et al. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp Biol Med (Maywood). May 2009;234(5):492-503. [Medline].

  92. Zhou T, Neubert H, Liu DY, Liu ZD, Ma YM, Kong XL, et al. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis. J Med Chem. Jul 13 2006;49(14):4171-82. [Medline].

  93. Emara AM, El Kelany RS, Moustafa KA. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Hum Exp Toxicol. Jul 2006;25(7):375-85. [Medline].

  94. Hazin R, Abu-Rajab Tamimi TI, Abuzetun JY, Zein NN. Recognizing and treating cutaneous signs of liver disease. Cleve Clin J Med. Oct 2009;76(10):599-606. [Medline].

  95. Khanna A, Jain A, Eghtesad B, et al. Liver transplantation for metabolic liver diseases. Surg Clin North Am. Feb 1999;79(1):153-62, ix. [Medline].

  96. Asare GA, Bronz M, Naidoo V, Kew MC. Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis. Toxicology. Dec 5 2008;254(1-2):11-8. [Medline].

  97. Aranda N, Viteri FE, Montserrat C, Arija V. Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Ann Hematol. Aug 2010;89(8):767-73. [Medline]. [Full Text].

  98. Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep. Mar 2007;9(1):74-82. [Medline].

  99. Imran F, Phatak P. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Expert Rev Pharmacoecon Outcomes Res. Aug 2009;9(4):297-304. [Medline].

  100. Lucotte G, Champenois T, Sémonin O. A rare case of a patient heterozygous for the hemochromatosis mutation C282Y and homozygous for H63D. Blood Cells Mol Dis. Sep-Oct 2001;27(5):892-3. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.